On 28 June, Gail Cassell, chair of the ASM Public and Scientific Affairs Board Committee on Biomedical Research, and Janet Shoemaker, ASM staff, were invited to meet with staff from the Senate Health, Education, Labor and Pensions (HELP) Committee, to discuss issues related to antibiotic resistance and the current status and incentives for the antibiotic product pipeline.
ASM also endorsed the Infectious Diseases Society of America's (IDSA) 10 × '20 Initiative which calls for a commitment by the U.S. Government and other governments around the world to create a sustainable antibiotic R&D enterprise which in the short term can produce 10 new antibiotics by 2020. Part of the initiative is to bring together experts from the industrial, medical, scientific, policy, regulatory, and financial communities to determine the combination of incentives that will work for the development of new antibiotics.
|
Public Affairs Report 
Facebook
del.icio.us
Digg
Furl 
Yahoo!My Web
StumbleUpon
Google
Technorati 
reddit
Twitter
